Honorem will participate in the 'BIO KOREA 2018' held at COEX from May 9th(Wed.) to 11th(Fri.) and show an one-stop clinical trial agent service.
Honorem with its head office in Singapore, as a specialized CRO in Asia, has a vision to be helpful in changing patients' lives innovatively and developing products which are be able to prolong patients' lives. Honorem though that domestic pharmaceutical companies' entry to Asia would be successful only when a systematical strategy is based, from the beginning of a clinical trial, so they have an ability to provide a consulting service throughout research from the beginning of development, namely material possibilities and targets, and clinical design and so on. They have currently branches in Korea and Taiwan, and have a plan to open branches in Japan and China in the near future.
Honorem is providing a clinical trial agent service to pharmaceutical companies. In general, they are dealing with rare or anticancer medicines. From RA stage, they understand the characteristics of rare medicines and anticancer medicines, and graft these onto a clinical operation plan. In particular, they have currently anticancer doctors who are directly involved in the medical writing stage from the strategy-establishment stage. Especially, they have great competitiveness in providing the best solution to partnerships by tracking clinical regulatory information and latest trend related to China.
Dr. Ethan Seah, CEO of Honorem participating in the Bio Korea this year, said "at this exhibition, we'd like to introduce more actively our name, Honorem, and our service to Korea market," and "Honorem as an One-stop Boutique CRO, is presenting a comprehensive strategy that considers from the development stage of medicine development to the stage after releasing the products in markets, and always providing the best quality of the products."
(Photo: Dr. Ethan Seah, CEO of Honorem)
Meanwhile, the BIO KOREA 2018, which has been 13 years this year, is expected to have around 25 thousand visitors from 45 countries for Asia largest sized bio and health industry convention. At a total of 19 conference sessions including the development trend of immuno-anticancer medicine, visitors can directly see the new paradigm of global health and the future of the next generation global healthy industry. Specialized unit events(Invest Fair, MedTech Fair, Job Fair, MedLab etc.) as well as an exhibition which can be seen only at the BIO KOREA international convention will play a role of catalysts for quantitative and qualitative growth throughout international health industry such as strengthening the international competitiveness of pharmaceutical and medical device industries, creating jobs, in addition to the investment vitalization opportunity for experts of health industry.